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Utility of 18F-FDG PET/CT in the Assessment of Lymphoepithelioma-like Carcinoma 
 
Objective: Lymphoepithelioma-like carcinoma (LELC) is a rare Epstein-Barr virus (EBV)-
related disease, which commonly originates from the lung and is associated with more 
favourable treatment outcomes compared to other non-LELC thoracic carcinomas. 
Radiological assessment utilizing 18Fluorine-fluorodeoxyglucose positron emission 
tomography combined with computed tomography (18F-FDG PET/CT) is important for initial 
disease staging to tailor the treatment strategy, evaluation of treatment response and detection 
of disease recurrence. The purpose of this article was to highlight the utility of 18F-FDG 
PET/CT in different stages of disease evaluation of LELC. 
Methods: We reviewed 7 patients with histologically proven LELC who underwent 18F-FDG 
PET/CT for disease evaluation.  
Results: We described the 18F-FDG avidity of LELC (ranged from SUVmax 7.6 to SUVmax 
14.5 in our series) and highlighted the clinical values of 18F-FDG PET/CT in different stages 
of disease evaluation. 18F-FDG PET/CT allows accurate evaluation of the primary tumour, its 
relationship with the surrounding structures and accurate staging. It is also useful in treatment 
response assessment to monitor the efficacy of the treatment and to decide upon treatment 
strategy. Given the 18F-FDG avidity of LELC, 18F-FDG PET/CT is advantageous in detecting 
tumour recurrence of LELC.  
Conclusion: LELC is a rare disease entity associated with EBV and is more prevalent in 
Asia, where EBV is endemic. LELC is FDG-avid tumour. Although the features on 18F-FDG 
PET/CT are not specific, 18FDG PET/CT offers valuable information on disease management 
of LELC. 
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Introduction 
Begin and associates first reported lymphoepithelioma-like carcinoma (LELC) in 1987 [1]. 
More than 150 cases were reported until 2006 [2]. The commonest site of primary tumour is 
the lung but LELC has also been reported in salivary glands, thymus, stomach, urogenital 
system and skin. LELC is closely associated with Epstein-Barr virus (EBV) infection and 
mostly seen in Asia with nearly two-thirds of the reported cases found in Taiwan, Southern 
China, and Hong Kong [3].  
 
On histology, LELC is similar to undifferentiated nasopharyngeal carcinoma (NPC). The 
tumour cells are arranged in nests or sheets with intense lymphoplasmacytic cell infiltration. 
The cell borders are ill-defined, giving rise to syncytial aggregation of tumour cells. The cell 
nuclei are round, oval, or elongated, with mildly irregular nuclear borders, clumped 
chromatin, and 1 or 2 distinct eosinophilic nucleoli. Association with EBV is observed 
mainly in LELC arising in the Asian population, which can be demonstrated by serologic, 
immunohistochemical, nucleic acid detection and in-situ hybridization techniques. In-situ 
hybridization using a sensitive digoxigenin-labelled RNA probe is the most commonly 
employed detection method for EBV- encoded small RNAs (EBER) [4]. Patchy expression 
of the viral latent membrane protein (LMP-1) can be demonstrated using 
immunohistochemistry [4]. In cancers that morphologically resemble LELC but which arise 
in Caucasians or in other organs such as skin, vagina and urinary bladder are not associated 
with EBV infection [3]. 
 
The most common type of LELC, pulmonary LELC, accounts for 0.9% of bronchogenic 
carcinoma [5]. The prognosis of pulmonary LELC is better compared to other non-LELC 
lung carcinoma; the 2-year and 5-year overall survival rates for pulmonary LELC were 
reported as 79.9% and 53.5% as compared to non-LELC lung carcinoma, which were lower 
at 59.5% and 39.1% respectively [3]. It is also indistinguishable from the metastasis 
originated from NPC. Therefore, nasopharyngeal origin needs to be excluded in all cases.  
According to WHO histological classification of lung tumours, pulmonary LELC belongs to 
a subtype of variants of large cell carcinoma [3].  
  
This article aimed to demonstrate the potential roles of 18F-FDG PET/CT in the assessment of 
LELC from initial disease detection to surveillance; allowing global reflection of metabolic 
active tumour burden in assisting treatment stratification and clinical management.  
 
Methods 
Seven cases selected for this atlas article were collected between November 2007 and April 
2015. All selected cases were histologically confirmed cases of LELC. There were 4 
pulmonary LELC and 3 non-pulmonary LELC. All examinations were performed using 
dedicated PET/CT scanner (Discovery VCT, 64-multislice CT, GE Healthcare Bio-Sciences 
Corp.), covering from the skull base to the upper thighs. Patients were required to fast for 6 
hours before the examination and the serum glucose was ensure not to exceed 180mg/dl 
before injecting 10mCi (370MBq) 18F-FDG. Image acquisition started at 60 minutes after 
18F-FDG injection. PET images were reconstructed using an ordered-subset expectation 
maximization iterative algorithm (14 subsets and two iterations) and CT was used for 
attenuation correction of the PET emission data. An experienced radiologist with 4 years 
experience in PET and more than 8 years experience in CT reviewed all the cases.  
 
Results and Discussion 
18FDG-avidity of LELC 
There is few published data, limiting to case reports, in the 18F-FDG-avidity of LELC [6-10]. 
All cases were 18F-FDG-avid with wide-range of reported maximum standardized uptake 
values (SUVmax), ranging from SUVmax 1.7 to SUVmax 34.5 [6, 7, 9]. The previous 
observation concurs with our experience in these 7 patients, whom the LELC was 
metabolically active, with SUVmax 7.6 to SUVmax 14.5. 
 
Primary Disease Detection 
18F-FDG PET/CT is able to detect primary site of LELC shortly after the development of 
clinical symptoms [6]. In locally advanced disease, 18F-FDG PET/CT allows accurate 
evaluation of the extent of the primary disease, its relationship with the local structures and 
resectability. We present a case of a 54-year-old woman who presented with new onset of 
cough. A lingular mass was found on CT thorax. Bronchoscopic biopsy confirmed the mass 
to be poorly differentiated carcinoma with suspicious LELC features; 18F-FDG PET-CT was 
performed for pre-operative assessment (Fig. 1). She went on to have a left pneumonectomy 
and LELC was confirmed. The integration of morphological and functional details allows 
18F-FDG PET/CT to be a more accurate imaging tool for primary disease assessment than CT 
or 18F-FDG PET alone.  
 
Staging 
18FDG PET/CT adopts a whole-body imaging coverage, allowing global evaluation of 
disease burden for accurate staging. Aside from the primary tumour, nodal and distant 
metastatic involvements are assessed. Distant organ metastases have not been previously 
described by other radiological studies on LELC [6, 7, 10-12]. Given the association with 
EBV, the nasopharynx, as included in the field of view on 18F-FDG PET/CT, should be 
carefully scrutinized for occult NPC. This is highlighted in a 60-year-old woman with a 
biopsy-confirmed LELC of the posterior mediastinal mass, the histology suggested that the 
primary tumour could be originating from the lung, thymus or nasopharynx. She was referred 
for 18FDG PET-CT to rule out NPC, other site of involvement and distant metastasis (Fig. 2). 
 
Accurate staging is crucial in deciding treatment strategy. Previous study showed that 
pulmonary LELC had preponderance for peribronchovascular and mediastinal spread [13]; 
hence, precise nodal staging is paramount in pulmonary LELC. Although tissue diagnosis 
remains important for small volume mediastinal disease, 18FDG PET/CT can aid in selecting 
the appropriate patients for more invasive mediastinal staging tests [14]. Surgery is the 
mainstay curative treatment for early stage pulmonary LELC, whereas combination therapy 
including adjuvant radiotherapy, chemotherapy or chemoradiation is required for more 
advanced disease [2]. 
 
Treatment Response Assessment 
In case of unexpected LELC, where diagnosis is made on resected specimen, post-operative 
18F-FDG PET/CT can provide information on residual disease and acts as baseline 
assessment prior to further therapy, if required. Furthermore, the changes in the 18F-FDG 
avidity and the sizes of the tumours can be useful in monitoring treatment response in 
subsequent follow-up. Here, we present a 66-year old man who had previous right upper 
lobectomy for pulmonary LELC. He suffered from disease recurrence in January 2015 and 
was given 4 cycles of chemotherapy. Pre-treatment and post-treatment 18FDG PET/CT scans 
were performed for treatment response assessment (Fig. 3). 18FDG PET/CT helps to identify 
patient who experiences progressive disease, to spare the patient from ineffective treatment 
and to offer alternative therapy.  
 
Detection of Recurrence 
Tumour progression could occur after years of stable disease. A 65-year-old woman, with 
diagnosis of stage IV pulmonary LELC in 2007, was previously treated by radiotherapy to 
mediastinum, followed by 6 cycles of chemotherapy. She remained in remission until early 
2010, when she complained of low back pain and pelvic pain. 18FDG PET/CT was requested 
to detect disease recurrence (Fig. 4). Disease surveillance is important; 18F-FDG PET/CT 
helps to differentiate tumour recurrence from benign pathology, such as that of post-
treatment changes and sometimes, infective entities.  
 
Non-pulmonary LELC 
Although pulmonary LELC is the most common type of LELC, it can affect other organs. 
These non-pulmonary LELC, including the recurrences, are 18FDG-avid in our experience.  
 
We present a case of thymic LELC in a 53-year-old man with symptoms of superior vena 
cava obstruction. Staging 18FDG PET/CT was performed (Fig. 5).  
 
Next, we present a 30-year-old man with limb numbness, weakness and muscle wasting; a 
clinical suspicion of myasthenia gravis was suspected. CT detected a huge anterior 
mediastinal mass with a left liver mass. Therefore, 18FDG PET/CT was subsequently 
requested for disease evaluation (Fig. 6). He underwent radical thymectomy, in which 
carcinoma of LELC variant was confirmed. 
 
Finally, we present a 66-year-old man, who was previously treated for LELC of the parotid 
gland in 1997 with right parotidectomy and radiotherapy. In 2015, he represented with 
hepatomegaly and EBV DNA was elevated to 42375 copies/ml. 18FDG PET/CT was 
performed to detect disease recurrence (Fig. 7).  
 
Conclusion 
LELC is a rare disease entity associated with EBV and is more prevalent in Asia, where EBV 
is endemic. LELC is 18FDG-avid tumour. Although the features on 18FDG PET/CT are not 
specific, 18FDG PET/CT offers valuable information on disease detection, staging, treatment 
response evaluation and disease surveillance.  
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Legends 
Fig. 1 
 
(A) Axial fused 18FDG PET/CT image shows a hypermetabolic lung mass extending from the 
left hilum to involve the apico-posterior segment of the left upper lobe, measuring 7.9 x 6.2 
cm with SUVmax 7.6, suggestive of primary lung carcinoma.  
(B) Coronal CT image shows the primary lung tumour infiltrating into the mediastinal fat, 
suggestive of early mediastinal invasion (arrow). 
(C) Hematoxylin and eosin section of LELC showing sheets of undifferentiated tumour cells 
admixed with abundant lymphoplasmacytic infiltrate (original magnification x 200). 
(D) In-situ hybridization with EBV- encoded small RNAs (EBER) probes showing diffuse 
strong nuclear signals (blue) in all tumour cells and absence of signals of surrounding stroma 
and inflammatory cells (original magnification x 200). 
  
Fig. 2 
 
(A) Axial fused 18FDG PET/CT image shows a hypermetabolic right posterior mediastinal 
mass (SUVmax 14.1). 
(B) Coronal fused 18FDG PET/CT image shows a hypermetabolic hepatic metastasis in 
segment 7 / 8 with central necrosis.  
(C) Axial fused 18FDG PET/CT image shows asymmetrical 18FDG uptake at the left 
nasopharynx with mild mucosal thickening (arrow). 
(D) Nasal endoscopy reveals irregular mucosal corresponding to the left nasopharynx uptake. 
Subsequent biopsy result was negative for malignancy, ruling out the presence of 
nasopharyngeal carcinoma. 
 
 
Fig. 3 
 
(A) 18FDG PET MIP image shows hypermetabolic disease recurrence adjacent to previous 
surgical resection with hypermetabolic right mediastinal nodal metastases and solitary distant 
osseous metastasis in the posterior left acetabulum.  
(B) Axial fused 18FDG PET/CT image shows tumour recurrence adjacent to the surgical 
resection margin, 2.8 x 2.2 cm with SUVmax 9.1. 
(C) 18FDG PET MIP image shows complete metabolic treatment response in the tumour 
recurrence and metastases following 4 cycles of chemotherapy.  
(D) Axial fused 18FDG PET/CT image shows complete resolution of the tumour recurrence 
and nodal metastases following chemotherapy. 
 
 
Fig. 4 
 
(A) 18FDG PET/CT in November 2007: 18FDG PET MIP image shows primary right middle 
lobe lung mass with mediastinal, right hilar and intra-abdominal nodal metastases. 
(B) 18FDG PET/CT in November 2007: Axial fused image shows right middle lobe tumour, 
which measures 4.5 x 3.5cm with SUVmax 12.5. 
(C) 18FDG PET/CT in February 2010: 18FDG PET MIP image shows apart from local 
thoracic disease recurrences, there are new hepatic metastases and bony metastases. 
(D) 18FDG PET/CT in February 2010: Axial fused 18FDG PET/CT image shows right middle 
lobe tumour recurrence, which measures 1.8 x 1.8cm with SUVmax 7.6.  
(E) 18FDG PET/CT in February 2010: Axial fused 18FDG PET/CT image shows a 
hypermetabolic hepatic metastasis. 
(F) 18FDG PET/CT in February 2010: Axial CT shows right ilium sclerotic osseous 
metastasis. 
Fig. 5  
 
(A) Axial fused 18FDG PET/CT image shows hypermetabolic anterior mediastinal mass, 
which measures 8.7 x 5.6 cm with heterogeneous 18FDG uptake (SUVmax 14.9). 
(B) Corresponding axial CT image shows the anterior mediastinal mass is partially encasing 
the superior vena cava and ascending aorta. 
(C) Axial fused 18FDG PET/CT image shows hypermetabolic tumour infiltration of both 
thyroid lobes. 
(D) Corresponding axial CT image shows heterogeneous enhancement of the right thyroid 
lobe, local invasion into the adjacent soft tissue and tumour thrombus in the right jugular vein 
(arrow). 
 
 
Fig. 6 
 
(A) Axial fused 18FDG PET/CT image shows a large hypermetabolic anterior mediastinal 
mass, 14.4 x 10.7 cm with SUVmax 14.5, which is indistinguishable from malignant 
lymphoma and thymic carcinoma 
(B) Axial fused 18FDG PET/CT image shows the extension of the hypermetabolic anterior 
mediastinal mass into the right hemithorax. 
(C) Sagittal CT image shows transcoelomic spread directly from mediastinum to liver 
(arrow). 
(D) Sagittal fused 18FDG PET/CT image shows the extension of 18FDG uptake from 
mediastinum to the dome of the liver (arrow). 
 
 
Fig. 7 
 
(A) 18FDG PET MIP shows the presence of hypermetabolic multi-compartmental 
lymphadenopathy, lung, liver and intra-peritoneal metastases. 
(B) Axial fused 18FDG PET/CT image shows hypermetabolic hepatic metastases and 
peritoneal metastases in the left paracolic gutter (arrow). 
 
